Surprise billing, also called surprise out-of-network balance billing, is a common problem when, through no fault of their own, families receive medical treatment from an out-of-network provider. The surprise comes in the form of doctor bills for the difference between what a provider charges and what the insurer pays that provider. Congress is currently considering legislation to address this problem for families all over the country. This piece describes the legislation under consideration in Congress and Families USA’s recommendations for a Congressional fix to this problem.
Amici Curiae Brief of Families USA, Community Catalyst, The National Health Law Program, The Center on Budget and Policy Priorities, and Service Employees International Union Supporting Intervenor Defendants-Appellants and Reversal of the District Court
Families USA filed an amicus brief in the Texas v. US case that threatens the entire Affordable Care Act, on appeal in the US Court of Appeals of the Fifth Circuit. Cosigners of the amicus include the Center on Budget and Policy Priorities, Community Catalyst, the National Health Law Program and the Service Employees International Union (SEIU).
Kansas lawmakers are currently considering legislation that could expand Medicaid to 150,000 nonelderly, low-income Kansans. As lawmakers debate Medicaid expansion in the state’s legislature, Families USA has published a fact sheet on the impact of Medicaid Expansion on Kansas’s state budget. Click here to view the fact sheet.
Federal Judge Boasberg struck down work requirements for the Medicaid program in both Arkansas and Kentucky. This March 28th webinar discussed the Judge's ruling and what it means for the future of Medicaid.
Featured speakers include:
- Eliot Fishman, Senior Director of Health Policy, Families USA
- Sophia Tripoli, Director of Health Care Innovations, Families USA
Oral health is an important factor to overall health and influences physical and mental well-being. People with mental health conditions and substance use disorders face a number of challenges that make them especially vulnerable to sub-par oral health. This factsheet provides an overview of how oral health and mental health interact, and provides solutions to improving oral care and access to this population.
On March 26, 2019, the chairs of three House committees with jurisdiction over core health care issues jointly introduced legislation that would lower health care costs for millions of people. The "Protecting Pre-Existing Conditions and Making Health Care More Affordable Act of 2019," would: increase financial assistance for families who buy their own insurance, without help from Medicaid, Medicare, or an employer; protect people with preexisting conditions by repealing Trump administration policies that sabotage the safe operation of insurance markets; and take other steps to help consumers understand and sign up for coverage.
State health plans for families are under scrutiny – in the courts, in the states, and in Washington. It is hard to think of a time when the Medicaid program was getting so much attention at one time outside of the halls of Congress.
The Trump administration’s efforts to restrict the health insurance program for America’s most vulnerable families are raising the profile of Medicaid and those who rely upon it for health care. Within weeks decisions are expected on the following:
From Trump administration block grant proposals, to work requirements in the federal courts, to the waiver restrictions faced in the Capitol hallways of West Virginia; Medicaid waivers are under scrutiny.
Speakers examine what's happening in the Trump administration and in the state capitols, as well as the hearings before US District Judge James Boasberg on work requirements in Arkansas and Kentucky. You will also learn how West Virginia advocates stopped a work requirement proposal in their state.
Eight in ten Americans say the cost of prescription drugs is “unreasonable.” This is a problem driven by high launch prices and price increases, which are rooted in drug corporations’ monopoly power and perverse incentives within the pharmaceutical supply chain.